Project Objectives

 
 

The primary objective of T.E.D. multicenter, prospective, observational electronic-based registry is to evaluate the outcome of Paclitaxel eluting Taxus Element stent in 750 Patients with diabetes mellitus who are suitable for drug-eluting stent implantation according to the applicable guidelines on percutaneous coronary interventions.

Exclusion criteria

1. Non-diabetic patients 

2. Primay intervention of acute ST elevation myocardial (STEMI) infarction

3. Use of a non Taxus Element stent in the index vessel.

 4. Taxus Element stent implantation in a vein graft or internal mammary graft.

5. High probability of non-compliance with study follow-up

 

 

Study End-Points

Primary end point:

MACE at 1 year consisting of cardiac death, non fatal myocardial infarction, and target vessel revascularization.

Secondary end points:

  • MACE at 2 years

  • Target vessel revascularization at 2 years.

  • Restenosis without TVR.

  • Role of diabetes treatment (insulin versus oral hypoglycaemic) on outcome.

  • Outcome in small vessels as a pre-specified sub-group as defined as ≤2.5 mm stent diameter.

  • Stent thrombosis yearly (according to the ARC definitions) up to 2 years.

 

 
     

 

 
 
 

|    HOME   |   CRF   |   Follow-up   |   Description   |   Objectives   |   Members   |   Mail   |   MOBILE Version   |  

 

| Developed & Operated By |

ęCopyright 2018 -  TED Registry.  All rights reserved. Reproduction of the material on this site and Database is prohibited without the consent of TED Principal Coordinating Center & The E-Medical DB Developer

Developed & Operated By Fourth Dimension Electronic Medical & Pharmaceutical Services INC.                                                                                                                                                            TORONTO - CANADA